Clinical Trial Update: Expanded Access to Navitoclax

View source ↗

Summary

Expanded access program for Navitoclax sponsored by AbbVie for myelofibrosis, acute lymphoblastic leukemia, and lymphoblastic lymphoma is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma
• Myelofibrosis

Drugs mentioned

• Navitoclax (navitoclax)

Snippet

Sponsor: AbbVie | Conditions: Myelofibrosis, Acute Lymphocytic Leukemia (ALL) | Status: NO_LONGER_AVAILABLE